Boston Scientific Announces February and March 2020 Conference Schedule

News provided by

Feb 18, 2020, 09:30 ET

MARLBOROUGH, Mass., Feb 18, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in three upcoming investor conferences.

On February 27, 2020, Susie Lisa, vice president, Investor Relations, will participate in a 25-minute question-and-answer session with the host analyst at the SVB Leerink 9^th Annual Global Healthcare Conference in New York City. The session will begin at approximately 10:30 a.m. EST.

On March 3, 2020, Dan Brennan, executive vice president and chief financial officer, and Susie Lisa will participate in a 30-minute question-and-answer session with the host analyst at Cowen and Company's 40^th Annual Health Care Conference in Boston. The session will begin at approximately 10 a.m. EST.

On March 11, 2020, Mike Mahoney, chairman and chief executive officer, and Lauren Tengler, director, Investor Relations, will participate in a 25-minute question-and-answer session with the host analyst at the Barclays Global Healthcare Conference in Miami. The session will begin at approximately 8 a.m. EDT.

A live webcast and replay of the webcast for each event will be accessible at investors.bostonscientific.com http://www.bostonscientific.com/investors. The replay will be available beginning approximately one hour following the completion of each event.

About Boston Scientific

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

CONTACTS
Media:	Investors:
Katie Schur	Susie Lisa, CFA
508-683-5574 (office)	508-683-5565 (office)
Media Relations	Investor Relations
Boston Scientific Corporation	Boston Scientific Corporation
[email protected]	[email protected]